CytoSorbents Corporation (CTSO)

[biotech48]

Rival Novartis, Gilead CAR-T therapies win CHMP recommendations
Jun. 29, 2018 9:27 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Carl Surran, SA News Editor
Rival cancer cell therapies from Novartis (NYSE:NVS) and Gilead Sciences (NASDAQ:GILD) win key recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use, likely clearing their way for approval.

CHMP recommends NVS’s Kymriah for treatment of B cell acute lymphoblastic leukaemia and diffuse large B cell lymphoma; the product already has been approved in the U.S.

The panel also recommends GILD's Yescarta, which also has U.S. approval in blood cancer, got the CHMP's nod for treatment of diffuse large B cell lymphoma, and would compete with the NVS medicine, as well as in primary mediastinal B-cell lymphoma and transformed follicular lymphoma.

The European Commission must issue final approval before the medicines can be sold in Europe.